Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction.

 

Abbott bioresorbable Absorb stent BVS
Feature | September 26, 2012

September 26, 2012 — Abbott Vascular this week began its international launch of the Absorb coronary stent, the...

News | August 14, 2012

August 14, 2012 — The U.S. Food and Drug Administration (FDA) is hosting a public workshop that examines use of...

News | July 17, 2012

July 17, 2012 — Arterial Remodeling Technologies (ART) reported that they have achieved a medical milestone with its...

News | July 16, 2012

July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting...

News | April 16, 2012

April 16, 2012 - 480 Biomedical announced that it has initiated the first human trial of its groundbreaking Stanza...

News | April 05, 2012

April 5, 2012 — Arterial Remodeling Technologies (ART) reported yesterday that in vivo data strongly suggest that...

Feature | March 27, 2012

March 27, 2012 — Biodegradable polymer drug-eluting stents...

Feature | March 16, 2012 | Mark Paquin

April 15, 2012, will mark the 10th anniversary of the approval of the first drug-eluting...

News | December 22, 2011

December 22, 2011 ­– Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe...

News | December 09, 2011

December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-...

News | November 15, 2011

November 15, 2011 – Abbott announced positive long-term data from the two-stage ABSORB trial, which is evaluating...

News | November 07, 2011

November 7, 2011 – Abbott announced the company's schedule of key data presentations at the 23rd annual...

News | November 07, 2011

November 7, 2011 – Arterial Remodeling Technologies (ART) reported that in vivo data strongly suggest that its...

News | October 24, 2011

October 24, 2011 — BioCrossroads’ Indiana Seed Fund has announced its twelfth investment...

News | October 18, 2011

October 18, 2011 — Abbott announced the investigational Absorb bioresorbable vascular scaffold (BVS) has been...

Overlay Init